Quanterix Corporation · NASDAQ:QTRX

Quanterix — Q3 2026 Earnings Presentation

21 slides from Quanterix's earnings presentation, Nov 9, 2026

  1. Slide 1: Q3 2026 Earnings Presentation

    Slide 1: Q3 2026 Earnings Presentation

    Q3 2026 Earnings Presentation Quanterix Corporation: (NASDAQ: QTRX) November 9, 2026 Everett Cunningham, Chief Executive Officer Jason Faessler, Chief Financial Officer

  2. Slide 2: Legal Information

    Slide 2: Legal Information

    Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this presentation that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provid

  3. Slide 3: Initial Signs of Restoring Growth and Sustaining Catalysts

    Slide 3: Initial Signs of Restoring Growth and Sustaining Catalysts

    Initial Signs of Restoring Growth and Sustaining Catalysts Initial Signs of Restoring Growth Slowing the Decline 50 -1% 0% • $35.0M in Q3 revenues, ahead of expectations, 6.3% higher than Q2 45 -5% -9% • Strong Q2 comparables in spatial consumables and the Americas -10% 40 • Growing Accelerator Lab

  4. Slide 4: Organizational Priorities

    Slide 4: Organizational Priorities

    Organizational Priorities Laser focus Strategic Scale AD on execution Roadmap Diagnostics Commercial organization Strengthening position in Dedicated Dx team to leadership and product- ultra-sensitive protein scale for growth: expand based approach focused detection along with IVD partnerships and b

  5. Slide 5: SIMOA

    Slide 5: SIMOA

    SIMOA Reinforcing our IVD strategy and strengthening our position in ultra-sensitive protein detection Platform Research & Translational Clinical & Diagnostics HD-X HD-X IVD RUO Planned submission SR-X SP-X in 2027 Recent launches: Q4’26 Plan: H1 2027 Plan: Neurological biomarker Menu • NPTX2 • MTBR

  6. Slide 6: Spatial

    Slide 6: Spatial

    Spatial Continue to improve features and usability with expanded menu launches Platform Discovery, Research & Translational PhenoCycler Fusion PhenoImager HT Oncology biomarker Recent launches: 2027 Plan: • ADC panel • Stromal, vasculature Menu themes: Extend coverage of • TiME panel and invasion Ha

  7. Slide 7: Spatial Oncology Menu Led by Hallmarks of Cancer

    Slide 7: Spatial Oncology Menu Led by Hallmarks of Cancer

    Spatial Oncology Menu Led by Hallmarks of Cancer Spatial Consumable revenue near record level in Q3, with further oncology opportunities Sustaining Evading IO60 Panel proliferative growth 60 plex foundational panel signaling suppressors Metabolism Panel Deregulating Avoiding Exploring energy path

  8. Slide 8: AD Diagnostics: Scalable foundation

    Slide 8: AD Diagnostics: Scalable foundation

    AD Diagnostics Leveraging Dx investment to build infrastructure, team, and network supporting growing LucentAD adoption Best-in-class Building Driving Multi-marker Test Infrastructure Adoption 100% 510(k) Submitted $897 patient readouts vs to FDA pricing received from CMS for LucentAD® 80% for compe

  9. Slide 9: AD Diagnostics: Continuing Commercial Adoption

    Slide 9: AD Diagnostics: Continuing Commercial Adoption

    AD Diagnostics: Continuing Commercial Adoption Demonstrating progressive expansion in serving the clinical market Notable additions in 2026 C O M M E R C I AL PAR T N E R S (Received China FDA) Growing Network of Labs (Received class-1 registration in Korea MFDS for HD-X) Developments in 2026 REIMBU

  10. Slide 10: Q3'26 Financial Update

    Slide 10: Q3'26 Financial Update

    Q3’26 Financial Update

  11. Slide 11: Q3'26 Financial Performance

    Slide 11: Q3'26 Financial Performance

    Q3’26 Financial Performance $35M 6% (13%) $81M As Reported Revenue QoQ Revenue Growth YoY Revenue Decline Cash Balance (in $M) (13%) (9%) Proforma Revenue Adjustments $40.2 $38.5 $35.0 $35.0 • $0.6M addition of Akoya pre- acquisition revenue in Q325 • ($2.4M) reduction in Q325 for terminated diagnos

  12. Slide 12: Q3'26 Revenue Performance

    Slide 12: Q3'26 Revenue Performance

    Q3’26 Revenue Performance Proforma revenue QoQ Comparisons Geography AMER up high teens % on commercial execution improvement EMEA down, reflecting seasonality APAC roughly flat for QoQ Products & Svcs Accelerator bookings up mid-teens % while revenue was flat sequentially SIMOA up LSD on instrument

  13. Slide 13: Q3'26 Financial Results vs Q3'25

    Slide 13: Q3'26 Financial Results vs Q3'25

    Q3’26 Financial Results vs Q3’25 (in $M, except percentages) Q3 GAAP Q3 Non-GAAP YTD GAAP YTD Non-GAAP 2026 2025* 2026 2025 Var % 2026 2025* 2026 2025 Var % Revenue 35.0 40.2 35.0 40.2 -13% 104.3 95.0 104.3 95.0 10% Gross Margin $ 13.5 15.9 16.6 18.5 -10% 41.7 40.7 50.9 43.8 16% Gross Margin % 38.6%

  14. Slide 14: Updating 2026 Guidance

    Slide 14: Updating 2026 Guidance

    Updating 2026 Guidance Narrowing Full Year Revenue Outlook: $142M to $146M Re-Affirming Adjusted Gross Margin (non-GAAP) Forecast: 48% to 50% Updated 2026 year-end cash balance of $70M 14

  15. Slide 15: Summary

    Slide 15: Summary

    Summary Meaningful progress in Q3, first step in return to growth journey Strengthened leadership, building momentum Reorganized sales team to sharpen accountability Confident in strength and positioning of Research Tools and Diagnostics businesses Focused on achieving key milestones ahead, includin

  16. Slide 16: Appendix

    Slide 16: Appendix

    Appendix

  17. Slide 17: Quanterix's Leadership Positioning in Proteomics

    Slide 17: Quanterix's Leadership Positioning in Proteomics

    Quanterix's Leadership Positioning in Proteomics Differentiated strength in ultra-sensitive blood biomarkers and high-plex spatial tissue analysis across the discovery-to-diagnostics continuum Proteomics Discovery Translational Diagnostics • Milli to Femto molar sensitivity • Pico to Atto molar sens

  18. Slide 18: Scientific Validation Driving Adoption

    Slide 18: Scientific Validation Driving Adoption

    Scientific Validation Driving Adoption Spatial SIMOA Number of Drug Trial Projects (Simoa Only) PUBLICATIONS BIOMARKERS INSTRUMENTS LAB SERVICES 7,110 768 780 2,538 2,610 304 2,365 53.8 702 283 6,257 670 189 189 2,155 642 2,742 134 44.5 15.8 111 104 205 1,810 5011 2,309 1439 1,480 1,439 1,330 1330 1

  19. Slide 19: Reconciliation of Adjusted EBITDA (non-GAAP)

    Slide 19: Reconciliation of Adjusted EBITDA (non-GAAP)

    Reconciliation of Adjusted EBITDA (non-GAAP) (in thousands, unaudited) Three Months Ended September 30, 2026 2025 Net loss $ (21,591) $ (33,517) Interest income (663) (1,448) Income tax benefit (expense) 288 (2,480) Depreciation and amortization 6,432 5,431 Stock-based compensation expense (1) 3,784

  20. Slide 20: Reconciliations of Adjusted Gross Profit, Gross Margin, Operating Expenses, and Loss

    Slide 20: Reconciliations of Adjusted Gross Profit, Gross Margin, Operating Expenses, and Loss

    Reconciliations of Adjusted Gross Profit, Gross Margin, Operating Expenses, and Loss (non-GAAP) (in thousands, except percentages, unaudited) Three Months Ended September 30, 2026 2025* Gross profit $ 13,500 $ 15,901 Purchase accounting impact on inventory and property and equipment (1) 205 35 2,53

  21. Slide 21: Contact Us

    Slide 21: Contact Us

    Contact Us General inquiries 900 Middlesex Turnpike, Billerica, MA 01821 USA 617.301.9400 info@quanterix.com www.quanterix.com

Source: 6ix earnings call

More decks from Quanterix Corporation

All 47 Quanterix decks